Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Xlife Sciences AG: New project in the portfolio

eqs_en 
0 0 04.11.19
Xlife Sciences AG: New project in the portfolio
 


DGAP-Media / 04.11.2019 / 07:35

We are pleased to announce that Xlife Sciences AG has added saniva diagnostics GmbH to the portfolio.

saniva diagnostics GmbH

Detecting diseases at an early stage is crucial to modern medical science. The timing of a diagnosis can significantly impact the chances of healing and the effectiveness of therapy. saniva diagnostics GmbH, a spin-off of the University Hospital Jena is developing a screening instrument to detect neurodegenerative diseases such as Parkinson or dementia at a very early stage. This screening instrument works by analyzing human movement.
For more information, please visit: www.sanivadiagnostics.com

Xlife Sciences AG

Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch



End of Media Release

Issuer: Xlife Sciences AG
Key word(s): Finance

04.11.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Xlife Sciences AG
Klausstrasse 19
8008 Zürich
Switzerland
Phone: 0041 44 385 84 60
E-mail: [email protected]
Internet: www.xlifesciences.ch
ISIN: CH0461929603
Listed: Regulated Unofficial Market in Munich
EQS News ID: 902715

 
End of News DGAP Media

902715  04.11.2019 

fncls.ssp?fn=show_t_gif&application_id=902715&application_name=news&site_id=sharewise

Xlife Sciences AG Stock

€42.20
-0.460%
The price for the Xlife Sciences AG stock decreased slightly today. Compared to yesterday there is a change of €0.000 (-0.460%).

Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!